News >

EFS at 24 Months May Predict Overall Survival in PTCL

Jason Harris
Published: Thursday, Nov 02, 2017

Andrew L. Feldman, MD
Andrew L. Feldman, MD
Patients with peripheral T-cell lymphoma (PTCL) are more likely to have superior overall survival (OS) if they have previously demonstrated event-free survival at 24 months (EFS24), according to findings published in the Journal of Clinical Oncology.

The researchers noted that patients aged 60 or younger (n = 137) had the most favorable outcomes after achieving EFS24, with a 5-year OS of 91% (versus 98% expected [control population]). Patients who received autologous stem cell transplantation (SCT) in first remission (n = 72) had a 5-year OS of 88% (vs 96% expected). Patients who did not receive autologous SCT who achieved EFS24 (n = 189) had a 5-year OS of 74% (vs 90% expected).
Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral t-cell lymphoma. J Clin Oncol [published online October 26, 2017]. doi: 10.1200/JCO.2017.73.8195.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x